Rituxan

Phase 2Biologic

Pfizer

Rituxan is one of 285 biologic programs targeting Acquired Hemophilia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

284

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acquired HemophiliaActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

Aplastic AnemiaActive, not recruiting

Thrombocytopenic PurpuraActive, not recruiting

LymphomaActive, not recruiting

Kidney TransplantActive, not recruiting

MelanomaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Pompe DiseaseActive, not recruiting

Idiopathic Inflammatory MyopathyActive, not recruiting

Acquired HemophiliaPhase 2/Phase 3

Active, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

Aplastic AnemiaPhase 1

Active, not recruiting

Thrombocytopenic PurpuraPhase 1

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Kidney TransplantPhase 1/Phase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Rheumatoid ArthritisPreclinical

Active, not recruiting

Pompe DiseasePhase 1

Active, not recruiting

Idiopathic Inflammatory MyopathyPhase 1

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Pfizer

Phase 2

4 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Zofran

Novartis

Preclinical

2 4

Tafasitamab

Incyte

Preclinical

7 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 7

PEG-Intron

Merck & Co.

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis7 trials

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01682512·294 enrolled

Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis

Completed·—·Phase 1/2·NCT02296775·276 enrolled

Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy

Completed·UUniversity of California, San Francisco·N/A·NCT00844714·20 enrolled

Show 4 more trials

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

Completed·AArchigen Biotech Limited·Phase 1·NCT02819726·294 enrolled

Completed·CCelltrion·Phase 3·NCT02149121·384 enrolled

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Completed· Pfizer logo

Pfizer·Phase 2·NCT01526057·220 enrolled

MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis

Withdrawn·MMabion SA·Phase 3·NCT04680962

Lymphoma4 trials

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

Completed·—·N/A·NCT01702961·75 enrolled

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01538472·40 enrolled

Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma

Completed·UUniversity of Nebraska·Phase 1/2·NCT00572013·32 enrolled

Show 1 more trial

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Terminated· Biogen logo

Biogen·Phase 3·NCT00057343·400 enrolled

Follicular Lymphoma2 trials

To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

Completed·CCelltrion·Phase 3·NCT02260804·258 enrolled

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

Completed·—·Phase 2·NCT00251394·30 enrolled

Kidney Transplant2 trials

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

Completed·UUniversity of Cincinnati·Phase 4·NCT00782821·40 enrolled

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

Completed·—·Phase 1/2·NCT01178216·41 enrolled

Pompe Disease1 trial

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

Completed·UUniversity of Florida·Phase 1·NCT02240407·2 enrolled

17 more indications

Refractory1 trial

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Completed· Novartis logo

Novartis·Phase 1/2·NCT01274182·312 enrolled

Stem Cell Transplantation1 trial

Stem Cell Transplantation for Stiff Person Syndrome (SPS)

Terminated·NNorthwestern University·Phase 1/2·NCT02282514·23 enrolled

Carboplatin1 trial

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00074165·17 enrolled

Aplastic Anemia1 trial

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03531736·17 enrolled

Intravenous1 trial

RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study

Completed· Pfizer logo

Pfizer··NCT06790420·1 enrolled

Efficacy1 trial

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

Completed·CCelltrion·Phase 3·NCT02162771·140 enrolled

Randomized1 trial

Randomized Double Cord Blood Transplant Study

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00067002·110 enrolled

Melanoma1 trial

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

Unknown status·CCalifornia Cancer Assocaties for Research & Excellence·Phase 2·NCT02142335·17 enrolled

Hematological Malignancies1 trial

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00566696·73 enrolled

Polyneuropathies1 trial

A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies

Unknown status·NNational Center for Research Resources (NCRR)·Phase 2·NCT00006072

Relapsed or Refractory1 trial

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Terminated·NNorthwestern University·Phase 1/2·NCT00089284·30 enrolled

Safety and Efficacy1 trial

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00496873·100 enrolled

Acquired Hemophilia1 trial

Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A

Terminated·GGeorgetown University·Phase 2/3·NCT00306670·2 enrolled

Thrombocytopenic Purpura1 trial

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Unknown status·NNew York Medical College·Phase 1·NCT04323748·20 enrolled

Idiopathic Inflammatory Myopathy1 trial

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

Terminated·NNorthwestern University·Phase 1·NCT00278564·7 enrolled

Tics1 trial

A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT01390441·100 enrolled

Systemic Lupus Erythematosus1 trial

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00076752·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 33 trial records for Rituxan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rituxan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rituxan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Rituxan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis7 trials

Lymphoma4 trials

Follicular Lymphoma2 trials

Kidney Transplant2 trials

Pompe Disease1 trial

Refractory1 trial

Stem Cell Transplantation1 trial

Carboplatin1 trial

Aplastic Anemia1 trial

Intravenous1 trial

Efficacy1 trial

Randomized1 trial

Melanoma1 trial

Hematological Malignancies1 trial

Polyneuropathies1 trial

Relapsed or Refractory1 trial

Safety and Efficacy1 trial

Acquired Hemophilia1 trial

Thrombocytopenic Purpura1 trial

Idiopathic Inflammatory Myopathy1 trial

Tics1 trial

Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News